Intralesional implant for treatment of primary oral malignant melanoma in dogs.
The feasibility, safety, and efficacy of a new method of local, sustained-release chemotherapy by use of intralesional cisplatin implants were evaluated in the treatment of oral malignant melanoma. The implant is an injectable viscous gel composed of a protein carrier matrix, a vasoactive modifier, and a chemotherapeutic drug. Twenty dogs with biopsy-proven melanomas were treated at 1- to 2-week intervals by injection with cisplatin implant. Tumors were treated until they resolved or were judged to be unresponsive. In 3 dogs with tumors unresponsive to cisplatin implants, methotrexate implants were used, and in 2 of these dogs, carmustine implants followed the methotrexate. Tumor responses were evaluated by sequential measurements. Melanomas in 14 (70%) of 20 dogs had a > 50% decrease in volume, and in 11 (55%) of these dogs, had a complete response. Tumors with complete responses received a mean cisplatin dose of 11.7 +/- 1.8 mg, delivered in a mean of 2.6 treatments. Two of the dogs with complete response also were treated with methotrexate and carmustine. Implants were well tolerated. Local necrosis, limited to the treatment site, developed in most tumors (17/20) and was associated with tumor response. Systemic toxicosis was minimal; renal insufficiency after cisplatin implants was not evident. Median survival times of dogs with complete tumor response (51 weeks) was substantially greater than that of dogs without local tumor control (10.5 weeks). Recursive partitioning analysis of variables indicated that mandibular tumors of short duration were associated with a positive outcome.(ABSTRACT TRUNCATED AT 250 WORDS)
Kitchell
B E
BE
Special Veterinary Services, Berkeley, CA 94704.
Brown
D M
DM
Luck
E E
EE
Woods
L L
LL
Orenberg
E K
EK
Bloch
D A
DA
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002330:Carmustine / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004343:Drug Implants; D005260:Female; D005782:Gels; D015552:Injections, Intralesional / Q000662:veterinary; D016014:Linear Models; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary*; D008727:Methotrexate / Q000008:administration & dosage; D009062:Mouth Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary; D009959:Oropharyngeal Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary*; D015996:Survival Rate; D016896:Treatment Outcome
D003692:Delayed-Action Preparations; D004343:Drug Implants; D005782:Gels; D002945:Cisplatin; D002330:Carmustine; D008727:Methotrexate